Best Prior Authorization Software: An Independent Comparison

This is the question that decides your shortlist, and most buyers skip it because the category name hides it. Prior authorization involves at least three parties, and vendors sell to all of them under the same three words.

• Provider side platforms build the packet, submit it, chase the status and work the denial. Waystar and Latent Health are examples. You buy these.
• Networks carry the transaction between provider and payer systems, and their value is a function of which payers they have connected. Availity and Rhyme are examples. You buy these too, but what you are really buying is coverage of your payer mix.
• Payer side platforms receive and decide the request. Cohere Health and Anterior are examples. You cannot buy these, and shortlisting them wastes a procurement cycle.

If your problem is that staff spend hours a day on hold and re-keying, you want the provider side or the network. If your problem is that a specific plan takes twelve days to decide, no purchase of yours changes that, and the conversation belongs in your payer contract negotiation instead. Our prior authorization automation use case works through where each of those costs actually sits.

Less of the end to end process than the marketing implies, and more of the boring middle than most buyers expect. The work splits into five steps, and vendors automate different subsets.

1. Determination. Does this order need an authorization for this plan and this member. This is rules lookup, and it is the most reliably automated step.
2. Packet assembly. Pulling the clinical evidence the payer will demand out of the chart. This is where large language models have genuinely changed what is possible, and also where they introduce the most review burden.
3. Submission. Portal, fax, phone or an application programming interface. Coverage varies by payer and this is where network vendors earn their fee.
4. Status chasing. The single largest consumer of staff hours, and the easiest thing to automate well.
5. Appeal. Drafting a rebuttal against a denial reason. Overlaps heavily with denial management and is often bought as part of that instead.

A vendor that automates determination and status chasing may cut your labour meaningfully without ever touching the clinical packet. That is a lower risk deployment and a faster one. Buyers who insist on automating packet assembly first take on a clinical review problem before they have taken the easy wins.

It changes the timeline you are buying against, not the decision itself. The CMS Interoperability and Prior Authorization Final Rule, CMS-0057-F, requires impacted payers, which include Medicare Advantage organisations, state Medicaid and CHIP fee for service programmes and qualified health plan issuers on the federally facilitated exchanges, to shorten decision timeframes and to publish authorization metrics, and then to stand up a standards based prior authorization application programming interface by 1 January 2027 according to CMS.

Two things follow for a provider buyer. First, some of the pain you are about to spend money on will be reduced by regulation on a known date, particularly status visibility. Second, the interface is coming whether or not your vendor is ready for it, so ask any shortlisted vendor for its written position on the payer facing API and the dates it is working to. A vendor that cannot answer that in August 2026 is not tracking its own market.

What the rule does not do is cover commercial plans that fall outside the impacted payer definition, and for many practices that is most of the book. Read the CMS prior authorization rule page for the applicability detail before you assume the problem solves itself.

Four axes matter, and none of them is the feature list.

• Payer coverage. The only number that predicts your result. Ask for coverage against your own top twenty payers by volume, in writing, before signing. Vendors quote national coverage percentages that are irrelevant to a practice with a regional payer mix.
• Where the work lands. Inside the EHR worklist, in a separate platform, or as a service that returns a result. Each demands a different amount of staff retraining, which is a real cost that no price list shows.
• Service level. Some vendors sell software, some sell software plus people working the exceptions. The second is more expensive and often cheaper overall, because the exceptions are where the hours are.
• Specialty fit. A radiology authorization queue and a specialty pharmacy queue are different jobs. Latent Health illustrates how narrow a credible product can be.

Integration depth is the axis most often overstated. A published integration means the vendor has done it somewhere, not that it is live in your build. Our Epic integration page sets out what to ask for so the answer is specific.

Only Availity publishes anything you can budget against, and what it publishes is that a provider portal tier is free. Every other vendor in this comparison quotes. That is not evasiveness so much as the shape of the market: pricing is usually a function of transaction volume, payer mix and how much exception handling the vendor absorbs, none of which fit on a pricing page.

Practically, the numbers you can control are on your side of the table. Count the authorizations you submit a month, the staff hours they consume, the share that are denied for administrative rather than clinical reasons, and the delay cost when a case slips. Those four figures let you set a ceiling before a single demo. The prior authorization cost calculator puts a number on the current state so the vendor's number has something to be compared against.

Watch three costs that sit outside the licence. Integration work is usually billed by your EHR vendor or your own team rather than the automation vendor. Staff retraining is real and lands in the first eight weeks. And exception handling does not disappear: if the vendor automates seventy percent of a queue, someone still owns the other thirty, and the residual work is harder on average than the work that was removed.

More than in the scribe market, and the gaps are worth naming.

We could not verify business associate agreement terms for Rhyme, Latent Health or Anterior from public sources. We could not verify named EHR integrations for four of the six vendors, because they describe integration generically rather than listing systems. And we could not verify any of the efficiency claims in this category independently: figures such as a large percentage reduction in authorization effort come from the vendor, measured on a customer population the vendor selected, with no published methodology.

That last point deserves emphasis because those numbers drive budget approvals. Treat every vendor percentage as a hypothesis to test in a pilot on your own payer mix, not as an input to a business case. If a vendor will not agree to measure the same figure in your environment during a pilot, that tells you what the number is worth.

Pick one service line and one payer set, and run the pilot there. Prior authorization behaviour varies so much by specialty and plan that an average across your whole organisation tells you almost nothing, and a pilot that spans everything takes a quarter to produce an ambiguous result.

Baseline four measures for six weeks before the vendor arrives: submissions per week, staff minutes per submission, days to decision, and administrative denial rate. Then run the same four measures for six weeks with the product. Agree in advance what result triggers a purchase, because the alternative is a decision made on how the demo felt.

Shortlist two vendors, not five. Every additional vendor in a pilot costs you scheduling, security review and staff attention, and consumes exactly the people you will need for the rollout. If you want a structured way through this, our vendor selection service exists because most organisations run this process once and vendors run it weekly.

More than with a scribe, because authorization packets move clinical evidence to a third party and then to a payer. The baseline is a signed business associate agreement, a documented answer on retention of the clinical attachments, a written position on whether your data trains any model, and access controls consistent with the rest of your estate.

Two extras are specific to this workflow. First, where a model drafts clinical justification, a named human must own the submitted content, because the assertion is going to a payer under your organisation's name. Second, medical necessity language generated by a model and submitted without review is a documentation integrity problem long before it is an AI problem. The HIPAA and AI compliance page covers the contractual side, and our HIPAA posture comparison shows which vendors across every category publish what.

Start by checking what you already own. A large share of practices are paying staff to do work by hand that the portal they already have partly automates, and a review of current tooling is the cheapest hour in this whole process. After that, measure the queue before shopping, because a vendor conversation without your own numbers is a conversation on the vendor's terms.

If authorization is one symptom of a wider revenue cycle problem, buying a point product will disappoint you. That case belongs with revenue cycle automation and a sequenced plan rather than a single purchase, and it is the situation where a deployment roadmap earns its fee: knowing what to buy second is worth more than a better answer on what to buy first. Hospital scale programmes have their own sequencing constraints, set out on our hospitals page.

The organisations that get value here are the ones that walked in knowing their own numbers, picked one queue, and measured the result. The ones that do not are the ones that bought a platform to solve a process problem they had never quantified.